Key facts
- It has raised $99.7M; the latest was Grant ($25.0M) in Sep 2024.
- Notable investors include MassChallenge, Khosla Ventures, 8VC, Felicis, The Engine — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Cellino
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellino are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellino
Developer of an AI-guided laser unwanted cells removal system designed for automated cell therapy. The company's system integrates image-guided machine learning, single-cell laser processing, and robotics to generate autologous induced pluripotent stem cells at scale, enabling healthcare providers to accelerate the development of personalized regenerative treatments while ensuring precision, efficiency, and scalability in optical bioprocess.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2017
- Employees
- 123
- Website
- cellinobio.com/
- Ownership
- Privately Held (backing)
Cellino doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellino shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellino in its N-PORT filings yet. We sweep new filings monthly.